Early weight loss from injectable pharmacotherapies in a person-centred multidisciplinary weight management service show comparable outcomes to the STEP-1 trial

Ehtasham Ahmad; Franciskos Arsenyadis; Hemlata Patel; Jessica Mehsuria; Gary Young; Thomas Dayman; Bernie Stribling; David Webb

doi:10.1530/endoabs.109.P149

P149

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 109 P149 | DOI: 10.1530/endoabs.109.P149

SFEBES2025 Poster Presentations Metabolism, Obesity and Diabetes (68 abstracts)

Early weight loss from injectable pharmacotherapies in a person-centred multidisciplinary weight management service show comparable outcomes to the STEP-1 trial

Ehtasham Ahmad ^1,2 , Franciskos Arsenyadis ^1,2 , Hemlata Patel ² , Jessica Mehsuria ³ , Gary Young ³ , Thomas Dayman ² , Bernie Stribling ^1,2 & David Webb ^1,2

Author affiliations

¹Leicester Diabetes Centre, University of Leicester, Leicester, United Kingdom; ²University Hospitals of Leicester NHS Trust, Leicester, United Kingdom; ³Leicestershire Partnership NHS Trust, Leicester, United Kingdom

Background: Phase 3 trials of glucagon-like peptide-1 receptor agonists (GLP-1RA) and glucose-dependent insulinotropic polypeptide (GIP)-based therapies have demonstrated clinically important short term weight loss (WL) in people living with obesity. Little prospective data exists showing efficacy of these medications in real world or clinic settings. We present real world 6-month outcomes for use of these medications prescribed through a tier 3 specialist weight management service (SWMS).

Methods: The Tier 3 SWMS at Leicester, Leicestershire and Rutland is a 3-year person-centred pilot commissioned through the local Integrated Care Board. Referrals were paused (n = 593) when the agreed pilot capacity was reached. The service commenced Jan 2024. We present efficacy data for the first patients receiving MDT-supported pharmacotherapies (Wegovy and Mounjaro reserved only for people with type 2 diabetes as per current NICE guidance) ) who have completed a minimum 6-months of treatment. Weight outcomes collected through clinic or primary care at 3 and 6 months and reported on electronic patient records. Completer and last observation carried forward analyses performed.

Results: Demographics include: 77.3% female with mean age of 47 years and with 57% belonging to White British ethnicity. Mean bodyweight and BMI were 128.5 kg and 45.8 kg/m², respectively. There were an average of 2.7 co-morbidities per patient. Compared to the STEP-1 trial, we report 10.2% WL (Wegovy: 10.9% n = 23, Mounjaro: 8.8%, n = 13) at the end of the first 6-months versus 10.4% (Wegovy) in the STEP-1 trial. Completers (n = 32) had 10.2% WL whilst including those ceasing treatment or missing data at 6 months (n = 36) had 9.9% Wl. Initial data show that clinical trial outcomes are replicated in the real world when delivered through a SWMS.

Conclusion: WL, discontinuations and complication outcomes of injectable GLP1-RA and GIP at 6 months in a Tier 3 SWMS were comparable to the STEP-1 trial.